1. Home
  2. MIRM vs FRSH Comparison

MIRM vs FRSH Comparison

Compare MIRM & FRSH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$79.34

Market Cap

4.2B

Sector

Health Care

ML Signal

HOLD

Logo Freshworks Inc.

FRSH

Freshworks Inc.

HOLD

Current Price

$12.28

Market Cap

3.7B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
MIRM
FRSH
Founded
2018
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
4.2B
3.7B
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
MIRM
FRSH
Price
$79.34
$12.28
Analyst Decision
Strong Buy
Buy
Analyst Count
11
16
Target Price
$92.45
$19.53
AVG Volume (30 Days)
809.5K
3.1M
Earning Date
11-04-2025
02-10-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$471,794,000.00
$810,640,000.00
Revenue This Year
$53.78
$18.20
Revenue Next Year
$19.91
$13.27
P/E Ratio
N/A
N/A
Revenue Growth
53.66
18.18
52 Week Low
$36.88
$10.51
52 Week High
$82.58
$19.77

Technical Indicators

Market Signals
Indicator
MIRM
FRSH
Relative Strength Index (RSI) 62.33 47.87
Support Level $77.99 $12.11
Resistance Level $82.58 $12.48
Average True Range (ATR) 3.21 0.32
MACD 1.03 -0.08
Stochastic Oscillator 83.25 12.10

Price Performance

Historical Comparison
MIRM
FRSH

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About FRSH Freshworks Inc.

Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CS and ITSM categories and has also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and serve their customers and employees. The group derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and Other regions.

Share on Social Networks: